(Reuters) - Pfizer Inc said its experimental breast cancer drug, in a mid-stage trial, showed a statistically significant improvement in patients' survival rates without their disease worsening. The drug palbociclib was tested in post-menopausal patients in combination with the hormonal therapy letrozole, and results were compared with patients receiving only letrozole. (Reporting by Esha Dey in Bangalore; Editing by Ted Kerr)
via Health News Headlines - Yahoo News http://ift.tt/1imvclr
No comments:
Post a Comment